Published in Mol Cancer Ther on June 01, 2010
Delivery of multiple siRNAs using lipid-coated PLGA nanoparticles for treatment of prostate cancer. Nano Lett (2011) 1.92
Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol (2013) 1.85
A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor. Asian J Androl (2011) 0.91
Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity. J Med Chem (2012) 0.82
A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer. PLoS One (2015) 0.78
Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. PLoS One (2012) 0.78
A good molecular target for prostate cancer chemotherapy. Asian J Androl (2011) 0.75
CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci (2004) 4.76
Mutant p53 drives invasion by promoting integrin recycling. Cell (2009) 4.75
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A (2009) 3.08
Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5. Biochemistry (2004) 2.95
Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate (2004) 2.49
Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell (2011) 2.40
Cellular functions of TIP60. Int J Biochem Cell Biol (2006) 2.28
P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat Commun (2011) 2.18
S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression. J Biol Chem (2006) 2.09
Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infection. Prostate (2013) 2.03
In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. Mol Cancer Ther (2004) 1.98
Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem (2002) 1.95
Kinesins and cancer. Nat Rev Cancer (2012) 1.84
Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res (2005) 1.83
Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology (2010) 1.81
TLR9 provokes inflammation in response to fetal DNA: mechanism for fetal loss in preterm birth and preeclampsia. J Immunol (2012) 1.63
The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Res (2008) 1.58
Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene (2003) 1.56
Automated analysis of vapor diffusion crystallization drops with an X-ray beam. Structure (2004) 1.53
Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res (2006) 1.52
A novel model of urinary tract differentiation, tissue regeneration, and disease: reprogramming human prostate and bladder cells into induced pluripotent stem cells. Eur Urol (2013) 1.51
Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells? BJU Int (2012) 1.51
Interaction of the mitotic inhibitor monastrol with human kinesin Eg5. Biochemistry (2003) 1.51
Motor-dependent microtubule disassembly driven by tubulin tyrosination. J Cell Biol (2009) 1.49
SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res (2009) 1.47
Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol Cell (2011) 1.44
Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53. Cancer Res (2011) 1.44
Kinesin-12, a mitotic microtubule-associated motor protein, impacts axonal growth, navigation, and branching. J Neurosci (2010) 1.40
The structure of the kinesin-1 motor-tail complex reveals the mechanism of autoinhibition. Science (2011) 1.39
Alternative splicing and biological heterogeneity in prostate cancer. Nat Rev Urol (2009) 1.33
Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene (2005) 1.33
Regulation of the androgen receptor by post-translational modifications. J Endocrinol (2012) 1.27
Pathways of proliferation and antiapoptosis driven in breast cancer stem cells by stem cell protein piwil2. Cancer Res (2010) 1.26
Sprouty and cancer: the first terms report. Cancer Lett (2006) 1.22
Regulation of the androgen receptor by SET9-mediated methylation. Nucleic Acids Res (2010) 1.17
Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3β. Cancer Res (2011) 1.17
A human T-cell lymphotropic virus type 1 enhancer of Myc transforming potential stabilizes Myc-TIP60 transcriptional interactions. Mol Cell Biol (2005) 1.15
Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. Cancer Res (2004) 1.15
Control of human PIRH2 protein stability: involvement of TIP60 and the proteosome. J Biol Chem (2003) 1.14
Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Mol Cell Biol (2006) 1.12
In situ lineage tracking of human prostatic epithelial stem cell fate reveals a common clonal origin for basal and luminal cells. J Pathol (2011) 1.12
New chemical tools for investigating human mitotic kinesin Eg5. Bioorg Med Chem (2007) 1.12
Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta (2012) 1.09
K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder. Dis Model Mech (2011) 1.08
Crystal structure of the motor domain of the human kinetochore protein CENP-E. J Mol Biol (2004) 1.04
Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5. J Med Chem (2008) 1.04
Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells. Prostate (2007) 1.04
An allosteric transition trapped in an intermediate state of a new kinesin-inhibitor complex. Biochem J (2009) 1.04
Ligands to FGF receptor 2-IIIb induce proliferation, motility, protection from cell death and cytoskeletal rearrangements in epithelial ovarian cancer cell lines. Growth Factors (2006) 1.03
Putative involvement of the histone acetyltransferase Tip60 in ribosomal gene transcription. Nucleic Acids Res (2004) 1.03
Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Oncogene (2002) 1.02
Deubiquitinating enzyme Usp12 is a novel co-activator of the androgen receptor. J Biol Chem (2013) 1.01
Advances in mouse models of prostate cancer. Expert Rev Mol Med (2008) 1.01
Identification of novel androgen-regulated pathways and mRNA isoforms through genome-wide exon-specific profiling of the LNCaP transcriptome. PLoS One (2011) 1.00
The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover. Nucleic Acids Res (2013) 1.00
Implementation of proteomic biomarkers: making it work. Eur J Clin Invest (2012) 1.00
Divergent routes to oral cancer. Cancer Res (2006) 0.99
Application of transcript profiling in formalin-fixed paraffin-embedded diagnostic prostate cancer needle biopsies. BJU Int (2008) 0.99
Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. J Clin Invest (2013) 0.99
Inhibition of ubiquitination and stabilization of human ubiquitin E3 ligase PIRH2 by measles virus phosphoprotein. J Virol (2005) 0.99
Vascular progenitor cells: origin and mechanisms of mobilization, differentiation, integration, and vasculogenesis. Stem Cells Dev (2005) 0.98
Targeting the EGFR-family for therapy: biological challenges and clinical perspective. Curr Pharm Des (2012) 0.97
Effects of dietary flavonoids on major signal transduction pathways in human epithelial cells. Biochem Pharmacol (2003) 0.97
Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J (2013) 0.96
Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer. PLoS One (2012) 0.96
Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents. J Mol Biol (2006) 0.96
SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis. EMBO Mol Med (2012) 0.96
FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth. Cancer Res (2010) 0.96
KDM4B is a master regulator of the estrogen receptor signalling cascade. Nucleic Acids Res (2013) 0.96
KGF suppresses alpha2beta1 integrin function and promotes differentiation of the transient amplifying population in human prostatic epithelium. J Cell Sci (2006) 0.96
Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecol Oncol (2011) 0.95
Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine. Cancer Res (2002) 0.95
The scaffolding protein RACK1 interacts with androgen receptor and promotes cross-talk through a protein kinase C signaling pathway. J Biol Chem (2003) 0.94
Application of Holistic Liquid Chromatography-High Resolution Mass Spectrometry Based Urinary Metabolomics for Prostate Cancer Detection and Biomarker Discovery. PLoS One (2013) 0.94
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model. Carcinogenesis (2008) 0.94
Use of hydrogen/deuterium exchange mass spectrometry and mutagenesis as a tool to identify the binding region of inhibitors targeting the human mitotic kinesin Eg5. Rapid Commun Mass Spectrom (2006) 0.93
GRP78 up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer. J Pathol (2010) 0.93
Ubiquitin-based probes prepared by total synthesis to profile the activity of deubiquitinating enzymes. Chembiochem (2012) 0.93
HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proc Natl Acad Sci U S A (2011) 0.92
Regulation of gene expression by the RNA-binding protein Sam68 in cancer. Biochem Soc Trans (2008) 0.91
Modelling synergistic interactions between HER2, Sprouty2 and PTEN in driving prostate carcinogenesis. Asian J Androl (2013) 0.91